06 Feb 2020 --- Nestlé Health Science (NHSc) is ramping up its investments, with a new strategic partnership with biotechnology company Valbiotis for the development and global commercialization of Totum-63. The patented combination of five plant extracts specifically designed to reduce the risk of developing Type 2 diabetes in prediabetics. Moreover, NHSc is poised to make an additional equity investment of US$200 million in food allergy solutions specialist Aimmune following FDA approval for its peanut therapy earlier this week. This brings Nestlé’s total investment in the biopharmaceutical company to US$473 million.
